Nivolumab significantly prolongs recurrence-free survival in resected stage II melanoma
Source: Healio, October 2022
Nivolumab conferred a statistically significant and clinically meaningful improvement in recurrence-free survival vs. placebo among patients with completely resected stage IIB or IIC melanoma, according to the agent’s manufacturer.
Results of a pre-specified interim analysis of the randomized phase 3 CheckMate -76K trial, — presented at 2022 Society for Melanoma Research Annual Meeting this week — showed a 58% reduction in the risk for recurrence or death with nivolumab (Opdivo, Bristol Myers Squibb), the company announced in press release. In addition, the PD-1 immune checkpoint inhibitor exhibited a safety profile consistent with prior studies, with no new safety signals.
“Within 5 years after surgery, one-third of stage IIB and one-half of IIC patients see their cancer return,” Georgina V. Long, AO, MD, PhD, co-medical director of Melanoma Institute Australia and chair of melanoma medical oncology and translational research at the institute and Royal North Shore Hospital at The University of Sydney, said in the press release. “[Nivolumab] could be an important treatment option for this patient population.”